New Report Assesses the Commercial Potential of Stem Cell-Based Therapies

Nov. 11, 2009 - PRLog -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report analysing stem call-based therapeutic delivery.

“Stem Cell-Based Therapeutic Delivery: Challenges & Opportunities”, which is available at bit.ly/4nKsNd, assesses the commercial potential of stem cell-based therapies in all of the key therapeutic areas: autoimmune diseases, cardiovascular, Central Nervous System (CNS) and hematological malignancies.

The 180 page report shows that stem cell-derived therapeutics are on the brink of a new era, with a handful of therapies expected on the market within the next two or three years. Big pharma and biotech companies such as Pfizer and Genyzme have recently invested large sums in this exciting and fast-moving area, further demonstrating its growing maturity.

Authors of the report note that stem cell therapies are already offered at various locations across the globe, including China and Thailand, despite a lack of robust, randomised clinical trials demonstrating their safety and efficacy. The fact that stem cell therapies are available in these locations and that patients' travel across the globe to receive them illustrates the high unmet medical need associated with some of the targets being investigated. Clinical evidence from high quality clinical trials is now imperative in order to protect these vulnerable patient populations.

However, the challenges facing companies developing stem cell-derived therapies are high and range from ethical discussions surrounding the use of human embryonic stem cells (hESCs) to difficulties associated with manufacture of cell-based products at scale and proving that products lack the potential to cause an immune response or cancer in a recipient. Nevertheless a growing pool of companies is investing heavily to bring this rapidly moving science to the clinic.

“Stem Cell-Based Therapeutic Delivery: Challenges & Opportunities” is available from Piribo. For more information go to: http://www.piribo.com/publications/therapeutic/stem_cellb...

Piribo product ID: PAV00008

# # #

About Piribo.
Piribo (http://www.piribo.com/publications/therapeutic/index.html) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 17,000 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.